New drug OPT101 takes first step: safety check in healthy volunteers
NCT ID NCT04589403
First seen Oct 31, 2025 · Last updated Apr 24, 2026 · Updated 29 times
Summary
This early-stage study tested the safety of a new drug called OPT101 in 14 healthy adults. Participants received either the drug or a placebo, and researchers monitored for side effects, vital signs, and lab changes. The goal was to find safe doses and understand how the body processes the drug, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
IMMUNOe Research
Centennial, Colorado, 80112, United States
Conditions
Explore the condition pages connected to this study.